Literature DB >> 20644995

Effects of mutant huntingtin on mGluR5-mediated dual signaling pathways: implications for therapeutic interventions.

Shan-Shan Huang1, Jun He, Dong-Ming Zhao, Xiao-Yuan Xu, Hui-Ping Tan, He Li.   

Abstract

Glutamate excitotoxicity is thought to play an important role in Huntington's disease (HD), which is caused by a polyglutamine expansion in the HD protein huntingtin (htt). Overactivation of group I metabotropic glutamate receptors (mGluRs), which include mGluR1 as well as mGluR5 and are coupled via phospholipase C to the inositol phosphate pathway, is found to be involved in mutant htt-mediated neurotoxicity. However, activation of mGluR5 also leads to neuronal protection. Here, we report that mutant htt can activate both mGluR5-mediated ERK and JNK signaling pathways. While increased JNK signaling causes cell death, activation of ERK signaling pathway is protective against cell death. Expression of mutant htt in cultured cells causes greater activation of JNK than ERK. These findings suggest that selective inhibition of the JNK signaling pathway may offer an effective therapeutic approach for reducing htt-mediated excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20644995     DOI: 10.1007/s10571-010-9543-7

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  39 in total

1.  Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity.

Authors:  Barbara L Apostol; Katalin Illes; Judit Pallos; Laszlo Bodai; Jun Wu; Andrew Strand; Erik S Schweitzer; James M Olson; Aleksey Kazantsev; J Lawrence Marsh; Leslie Michels Thompson
Journal:  Hum Mol Genet       Date:  2005-12-05       Impact factor: 6.150

2.  Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease.

Authors:  F R Fusco; Q Chen; W J Lamoreaux; G Figueredo-Cardenas; Y Jiao; J A Coffman; D J Surmeier; M G Honig; L R Carlock; A Reiner
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

3.  Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95.

Authors:  Y Sun; A Savanenin; P H Reddy; Y F Liu
Journal:  J Biol Chem       Date:  2001-04-23       Impact factor: 5.157

Review 4.  Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity.

Authors:  S Nakanishi
Journal:  Neuron       Date:  1994-11       Impact factor: 17.173

5.  Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling pathways.

Authors:  Sukhwinder Thandi; Jonathan L Blank; R A John Challiss
Journal:  J Neurochem       Date:  2002-12       Impact factor: 5.372

Review 6.  Excitotoxic injury of the neostriatum: a model for Huntington's disease.

Authors:  M DiFiglia
Journal:  Trends Neurosci       Date:  1990-07       Impact factor: 13.837

Review 7.  Chronic activation of ERK and neurodegenerative diseases.

Authors:  Luca Colucci-D'Amato; Carla Perrone-Capano; Umberto di Porzio
Journal:  Bioessays       Date:  2003-11       Impact factor: 4.345

8.  A sensitive and selective assay of neuronal degeneration in cell culture.

Authors:  Raeann L Carrier; Thong C Ma; Karl Obrietan; Kari R Hoyt
Journal:  J Neurosci Methods       Date:  2006-02-17       Impact factor: 2.390

9.  Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5.

Authors:  L P Daggett; A I Sacaan; M Akong; S P Rao; S D Hess; C Liaw; A Urrutia; C Jachec; S B Ellis; J Dreessen
Journal:  Neuropharmacology       Date:  1995-08       Impact factor: 5.250

10.  Huntington's disease gene (IT15) is widely expressed in human and rat tissues.

Authors:  S H Li; G Schilling; W S Young; X J Li; R L Margolis; O C Stine; M V Wagster; M H Abbott; M L Franz; N G Ranen
Journal:  Neuron       Date:  1993-11       Impact factor: 17.173

View more
  6 in total

1.  Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.

Authors:  Melissa R Sarantos; Theodora Papanikolaou; Lisa M Ellerby; Robert E Hughes
Journal:  J Huntingtons Dis       Date:  2012

2.  A novel target for Huntington's disease: ERK at the crossroads of signaling. The ERK signaling pathway is implicated in Huntington's disease and its upregulation ameliorates pathology.

Authors:  László Bodai; J Lawrence Marsh
Journal:  Bioessays       Date:  2012-02       Impact factor: 4.345

3.  Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats.

Authors:  T C H Leung; C N P Lui; L W Chen; W H Yung; Y S Chan; K K L Yung
Journal:  ACS Chem Neurosci       Date:  2011-10-26       Impact factor: 4.418

Review 4.  The extracellular signal-regulated kinase 1/2 pathway in neurological diseases: A potential therapeutic target (Review).

Authors:  Jing Sun; Guangxian Nan
Journal:  Int J Mol Med       Date:  2017-04-21       Impact factor: 4.101

5.  Ceftriaxone Treatment for Neuronal Deficits: A Histological and MEMRI Study in a Rat Model of Dementia with Lewy Bodies.

Authors:  Ying-Jui Ho; Jun-Cheng Weng; Chih-Li Lin; Mei-Shiuan Shen; Hsin-Hua Li; Wen-Chieh Liao; Nu-Man Tsai; Ching-Sui Hung; Te-Jen Lai; I-Yen Lee
Journal:  Behav Neurol       Date:  2018-08-01       Impact factor: 3.342

6.  Disruption of zinc transporter ZnT3 transcriptional activity and synaptic vesicular zinc in the brain of Huntington's disease transgenic mouse.

Authors:  Li Niu; Li Li; Shiming Yang; Weixi Wang; Cuifang Ye; He Li
Journal:  Cell Biosci       Date:  2020-09-11       Impact factor: 7.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.